CDT Equity Inc. Common Stock

CDT

Market cap $1.83M

Overview Fund Activity

0.6000 USD

0.0000

0%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

0.6123

+0.0123

2.05%

1 day

0%

5 days

-32.85%

1 month

-65.52%

3 months

-75.71%

6 months

-96.36%

Year to date

-99.47%

1 year

-99.71%

5 years

-100%

10 years

-100%

About: CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Employees: 6

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

2.09% more ownership

Funds ownership: 0.51% [Q1] → 2.61% (+2.09%) [Q2]

55% less funds holding

Funds holding: 31 [Q1] → 14 (-17) [Q2]

85% less capital invested

Capital invested by funds: $387K [Q1] → $56.4K (-$331K) [Q2]

89% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 19

See Fund Rankings

Financial journalist opinion

CDT Equity Identifies New Biological Target Validating AI-Driven Repurposing Strategy

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 26, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announces that it has successfully identified a new biological target and novel therapeutic indication for its lead programme, AZD1656 (and its derivatives), following positive data from pre-clinical studies.

CDT Equity Identifies New Biological Target Validating AI-Driven Repurposing Strategy

Conduit to Change Name to CDT Equity Inc.

Name change to CDT Equity Inc. reflects evolution of strategy and focus on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation, strategic partnerships and out-licensing NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit" or the “Company”) today announce that it intends to change its name to CDT Equity Inc. (“CDT”) reflecting the evolution of its strategy as a data-driven biotech development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships.

Conduit to Change Name to CDT Equity Inc.

Conduit Engages Consultant to Explore Cryptocurrency Reserve Strategy

Independent advisor appointed to assess feasibility and strategic benefit of a partial cryptocurrency-based treasury reserve Initiative aims to diversify capital positioning while retaining focus on IP-driven pharmaceutical development NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 08, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”) today announced that it has engaged a third-party consultant to evaluate and advise on the potential adoption of a part cryptocurrency treasury reserve strategy.

Conduit Engages Consultant to Explore Cryptocurrency Reserve Strategy

Conduit Pharmaceuticals Files New Patents Following AI-Driven Combination Discoveries

Includes Conduit's first composition of matter patent filing for AZD5658 and multiple new combination filings for AZD1656 and AZD5658 Patents derived from AI-led analysis conducted in partnership with Sarborg Limited NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit" or the “Company”) today announces the filing of four new patent applications relating to its key assets AZD1656 and AZD5658, including the Company's first patent filings for AZD5658.

Conduit Pharmaceuticals Files New Patents Following AI-Driven Combination Discoveries

Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health

Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in the $15 billion animal health market Evaluation of AZD5658 expands Conduit's glucokinase activator platform into novel veterinary applications, complementing AZD1656 development Cost-efficient approach enhances Conduit's pipeline while preserving full ownership of intellectual property and data, maximizing shareholder value Synergistic combination therapies under evaluation could redefine treatment standards in veterinary and human applications NAPLES, Fla. and CAMBRIDGE, United Kingdom, June 04, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”) today announced that it has entered into a joint development agreement with Manoira Corporation (“Manoira”), a privately held specialty animal health company specializing in proprietary reformulation technologies to create novel therapeutics for veterinary and livestock applications.

Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health

Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market

NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 22, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announces that, following confirmation of compliance with the Bid Price and Equity Requirements as detailed in the announcement dated May 21, 2025, the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company's application to transfer the listing of its common stock to The Nasdaq Capital Market has been approved and the Company's securities will be transferred to The Nasdaq Capital Market at the opening of business on May 23, 2025.

Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market

Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance

Conduit regains compliance with Bid Price and Equity Requirements CDT will continue to be listed and traded on The Nasdaq Stock Market NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 21, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announced that the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq's minimum bid price requirement (the “Bid Price Requirement”) set forth in Nasdaq Listing Rule 5550(a)(2), as well as Nasdaq's stockholders' equity requirement (“Equity Requirement”) set forth in Nasdaq Listing Rule 5550(b)(1).

Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance

Conduit Pharmaceuticals Inc. Announces Reverse Stock Split

NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 16, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announces that its board of directors has approved a 1-for-15 reverse stock split of the Company's common stock.

Conduit Pharmaceuticals Inc. Announces Reverse Stock Split

Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

Conduit secures a composition of matter patent from the Korean Intellectual Property Office for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships. NAPLES, Fla.

Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset

New patent filing secures composition of matter protection for AZD5904, a potent myeloperoxidase inhibitor in Conduit's pipeline, unlocking up to 20 years of new IP runway and enabling enhanced formulation strategies to target a broad range of diseases. NAPLES, Fla.

Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset

See News Rankings

Charts implemented using Lightweight Charts™